GSK (GSK) said Monday China's National Medical Products Administration has approved Blenrep in combination with bortezomib and dexamethasone to treat certain relapsed or refractory multiple myeloma patients.
The approval covers adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
Multiple myeloma is a type of blood cancer.